Silence Therapeutics PLC (SLN) News

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming...

Silence Therapeutics to Present at the Jefferies Healthcare Conference

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN...

Silence Therapeutics Reports First Quarter 2023 Results

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming...

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN...

Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming...

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Investor Conference

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming...

Silence Therapeutics Announces Publication in Blood Demonstrating Role for Iron Regulation in Polycythemia Vera

– Study provides therapeutic rationale for SLN124, Silence’s clinical candidate for polycythemia vera and other hematological disorders Silence...

Silence Therapeutics to Present at Guggenheim’s Genomic Medicines and Rare Disease Days

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       FORM...

Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development

Dr. Romano will succeed Dr. Giles Campion, CMO and Head of R&D, following his retirement by year-end Silence Therapeutics plc, Nasdaq: SLN...

Silence Therapeutics to Buyback siRNA Complement Assets

Deal gives Silence exclusive worldwide rights to two siRNA complement assets Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”...